Dudediligence.

Arrowhead Pharmaceuticals, Inc

ARWRNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

141.1M

on 2026-06-30, from 124.1M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

50M100M150MMar2024JunSepDecMar2025JunSepDecMar2026$64.50Jun

Newest

None

No S-3 or F-3 shelf on file in the last 30 months.

None

No at-the-market programme on file in the last 30 months.

Warrants

The 10-Q filed 2026-08-04 is not read yet.

Cash

108.5 quarters

$1.60B on 2026-06-30 ÷ $14.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-01-07Public offering incl. 1.55M pre-funded3,100,776$64.50$200.0M424B5 ↗

Also on file: $625.0M convertible notes, 2026-01-07 424B5 ↗ · $75.0M convertible notes, 2026-01-07 8-K ↗ · $75.0M convertible notes, 2026-01-12 8-K ↗